Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.

ABSTRACT:

Importance

Prognostic models may provide insight into clinical trial results and inform the clinical management of patients with BRAF V600-mutated metastatic melanoma.

Objective

To identify subgroups with distinct survival outcomes based on clinical and genomic characteristics and to assess survival in identified prognostic subgroups across cohorts treated with dacarbazine, vemurafenib, or cobimetinib plus vemurafenib.

Design, setting, and participants

This retrospective and exploratory recursive partitioning analysis (RPA) modeled associations between prespecified covariates and survival outcomes using pooled data from the BRIM-2, BRIM-3, BRIM-7, and coBRIM studies.

Interventions

Dacarbazine, vemurafenib, or cobimetinib plus vemurafenib.

Main outcomes and m

SUBMITTER: Hauschild A 

PROVIDER: S-EPMC6233771 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature